Anticorpo humanizado (Galician Wikipedia)

Analysis of information sources in references of the Wikipedia article "Anticorpo humanizado" in Galician language version.

refsWebsite

Global rank Galician rank

8nih.gov

4^th place

6^th place

8doi.org

2^nd place

7^th place

2clinicaltrials.gov

5,225^th place

7,257^th place

1archive.org

6^th place

8^th place

1drugbank.ca

4,294^th place

4,738^th place

1theraclone-sciences.com

low place

1web.archive.org

1^st place

archive.org

Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I. (May 1997). "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells.". J Immunol Methods 204 (1): 77–87. PMID 9202712. doi:10.1016/S0022-1759(97)00034-3.

clinicaltrials.gov

doi.org

dx.doi.org

Riechmann L, Clark M, Waldmann H, Winter G (1988). "Reshaping human antibodies for therapy". Nature 332 (6162): 332–323. PMID 3127726. doi:10.1038/332323a0.
Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. (Dec 1989). "A humanized antibody that binds to the interleukin 2 receptor.". Proc Natl Acad Sci U S A. 86 (24): 10029–33. PMC 298637. PMID 2513570. doi:10.1073/pnas.86.24.10029. (Este é un dos primeiros exemplos do uso do termo "anticorpo humanizado".)
Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I. (May 1997). "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells.". J Immunol Methods 204 (1): 77–87. PMID 9202712. doi:10.1016/S0022-1759(97)00034-3.
Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J. (May 2005). "SDR grafting—a new approach to antibody humanization.". Methods 36 (1): 25–34. PMID 15848072. doi:10.1016/j.ymeth.2005.01.003.
Hou S, Li B, Wang L, Qian W, Zhang D, Hong X, Wang H, Guo Y (July 2008). "Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modeling.". J Biochem 144 (1): 115–20. PMID 18424812. doi:10.1093/jb/mvn052.
Kempeni J. (Nov 1999). "Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7". Ann Rheum Dis 58 (Suppl 1): I70–2. PMC 1766582. PMID 10577977. doi:10.1136/ard.58.2008.i70.
Rau R (Nov 2002). "Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials". Ann Rheum Dis 61 (Suppl 2): 70–3. PMC 1766697. PMID 12379628. doi:10.1136/ard.61.suppl_2.ii70.
Stacy JE, Kausmally L, Simonsen B, Nordgard SH, Alsøe L, Michaelsen TE, Brekke OH (Dec 2003). "Direct isolation of recombinant human antibodies against group B Neisseria meningitidis from scFv expression libraries". J Immunol Methods 283 (1-2): 247–59. PMID 14659916. doi:10.1016/j.jim.2003.09.015.

drugbank.ca

DrugBank entry for alemtuzumab

nih.gov

ncbi.nlm.nih.gov

Riechmann L, Clark M, Waldmann H, Winter G (1988). "Reshaping human antibodies for therapy". Nature 332 (6162): 332–323. PMID 3127726. doi:10.1038/332323a0.
Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. (Dec 1989). "A humanized antibody that binds to the interleukin 2 receptor.". Proc Natl Acad Sci U S A. 86 (24): 10029–33. PMC 298637. PMID 2513570. doi:10.1073/pnas.86.24.10029. (Este é un dos primeiros exemplos do uso do termo "anticorpo humanizado".)
Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I. (May 1997). "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells.". J Immunol Methods 204 (1): 77–87. PMID 9202712. doi:10.1016/S0022-1759(97)00034-3.
Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J. (May 2005). "SDR grafting—a new approach to antibody humanization.". Methods 36 (1): 25–34. PMID 15848072. doi:10.1016/j.ymeth.2005.01.003.
Hou S, Li B, Wang L, Qian W, Zhang D, Hong X, Wang H, Guo Y (July 2008). "Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modeling.". J Biochem 144 (1): 115–20. PMID 18424812. doi:10.1093/jb/mvn052.
Kempeni J. (Nov 1999). "Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7". Ann Rheum Dis 58 (Suppl 1): I70–2. PMC 1766582. PMID 10577977. doi:10.1136/ard.58.2008.i70.
Rau R (Nov 2002). "Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials". Ann Rheum Dis 61 (Suppl 2): 70–3. PMC 1766697. PMID 12379628. doi:10.1136/ard.61.suppl_2.ii70.
Stacy JE, Kausmally L, Simonsen B, Nordgard SH, Alsøe L, Michaelsen TE, Brekke OH (Dec 2003). "Direct isolation of recombinant human antibodies against group B Neisseria meningitidis from scFv expression libraries". J Immunol Methods 283 (1-2): 247–59. PMID 14659916. doi:10.1016/j.jim.2003.09.015.

theraclone-sciences.com

http://www.theraclone-sciences.com/pdf/Theraclone_ISTAR.pdf Arquivado 03 de marzo de 2016 en Wayback Machine. Exemplo de método utilizando pacientes humano como fonte de anticorpos monoclonais.

web.archive.org

http://www.theraclone-sciences.com/pdf/Theraclone_ISTAR.pdf Arquivado 03 de marzo de 2016 en Wayback Machine. Exemplo de método utilizando pacientes humano como fonte de anticorpos monoclonais.